By the end of year 2019, the new virus SARS-CoV-2 appeared, causing the Coronavirus Disease 2019 (COVID-19), and spread very fast globally . A continuing need for diagnostic tools is a must to contain its spread . Till now, the gold standard method, the reverse transcription polymerase chain reaction (RT-PCR), is the precise procedure to detect the virus . However, SARS-CoV-2 may escape RT-PCR detection for several reasons . The development of well-designed, specific and sensitive serological test like enzyme immunoassay (EIA) is needed . This EIA can stand alone or work side by side with RT-PCR . In this study, we developed several EIAs including plates that are coated with either specially designed SARS-CoV-2 nucleocapsid or surface recombinant proteins . Each protein type can separately detect anti-SARS-CoV-2 IgM or IgG antibodies . For each EIAs, the cut-off value, specificity and sensitivity were determined utilizing RT-PCR confirmed Covid-19 and pre-pandemic healthy and other viruses-infected sera . Also, the receiver operator characteristic (ROC) analysis was performed to define the specificities and sensitivities of the optimized assay . The in-house EIAs were validated by comparing against commercial EIA kits . All in-house EIAs showed high specificity (98-99 %) and sensitivity (97.8-98.9 %) for the detection of IgG/IgM against RBD and N proteins of SARS-CoV-2 . From these results, the developed Anti-RBD and anti-N IgG and IgM antibodies EIAs can be used as a specific and sensitive tool to detect SARS-CoV-2 infection, calculate the burden of disease and case fatality rates.